Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers

An Open-Label, Multicenter, Phase II Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Serplulimab and Either Trastuzumab or Pertuzumab in Patients With HER2-Low Advanced Unresectable Gastrointestinal Cancers

This is an open-label, multicenter, Phase II clinical study designed to evaluate the effectiveness and safety of HLX22 in combination with serplulimab and either trastuzumab or pertuzumab in patients with HER2-low advanced gastrointestinal cancers.

The study will enroll approximately 128 adults with advanced unresectable colorectal cancer, gastric cancer (including gastroesophageal junction cancer), or biliary tract cancer who have experienced treatment failure after at least two prior lines of standard therapy.

Participants will receive HLX22, serplulimab, and either trastuzumab or pertuzumab by intravenous infusion every three weeks. The primary objective is to evaluate progression-free survival (PFS), which measures how long patients live without their cancer worsening. The study will also assess tumor response, overall survival, and treatment-related side effects.

Studie Overzicht

Gedetailleerde beschrijving

This study investigates a combination treatment strategy involving dual HER2-targeted monoclonal antibodies and PD-1 blockade in patients with HER2-low advanced gastrointestinal cancers. HLX22 is an investigational anti-HER2 monoclonal antibody that binds to a different epitope within the same HER2 extracellular domain as trastuzumab, allowing simultaneous binding. The study aims to explore the potential antitumor activity and tolerability of this combination in patients with limited treatment options following standard therapies.

The study consists of four treatment cohorts:

  • Cohort A (Colorectal Cancer, n=37): Serplulimab + HLX22 + Trastuzumab.
  • Cohort B (Gastric Cancer, including Gastroesophageal Junction Cancer, n=31): Serplulimab + HLX22 + Trastuzumab.
  • Cohort C1 (Biliary Tract Cancer, n=30): Serplulimab + HLX22 + Trastuzumab.
  • Cohort C2 (Biliary Tract Cancer, n=30): Serplulimab + HLX22 + Pertuzumab.

All study treatments are administered intravenously in 21-day cycles. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or another protocol-specified reason for discontinuation.

Tumor assessments will be performed according to RECIST version 1.1. Efficacy and safety outcomes will be evaluated during treatment and follow-up.

Studietype

Ingrijpend

Inschrijving (Geschat)

128

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Hubei
      • Wuhan, Hubei, China, 430022
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Voluntary participation in the study, provision of written informed consent, and willingness and ability to comply with all study procedures.

  2. Male or female participants aged 18 years or older at the time of informed consent.

  3. Histologically or cytologically confirmed advanced unresectable HER2-low colorectal cancer, gastric cancer (including gastroesophageal junction cancer), or biliary tract cancer, with failure of at least two prior lines of standard therapy. HER2-low expression is defined as IHC 1+ or IHC 2+ with negative in situ hybridization (ISH) in primary or metastatic tumor tissue.

  4. At least one measurable lesion according to RECIST version 1.1. Target lesions cannot consist solely of bone metastases.

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 within 7 days before the first dose.

  6. Life expectancy of at least 6 months.

  7. No evidence of active hepatitis.

  8. Negative hepatitis C virus (HCV) antibody test, or negative HCV RNA if HCV antibody-positive. Participants with concurrent hepatitis B and C infection are excluded.

  9. Adequate organ function, meeting all of the following criteria:

    • Absolute neutrophil count ≥1.5 × 10⁹/L.
    • Platelet count ≥90 × 10⁹/L.
    • Hemoglobin ≥90 g/L.
    • Total bilirubin ≤1.5 × upper limit of normal (ULN).
    • ALT and AST ≤2.5 × ULN (≤5 × ULN for patients with liver metastases).
    • Alkaline phosphatase ≤2.5 × ULN (≤5 × ULN for patients with liver and/or bone metastases).
    • Albumin ≥30 g/L.
    • Creatinine clearance ≥50 mL/min (Cockcroft-Gault formula).
    • APTT, PT, and INR ≤1.5 × ULN.

    Participants must not have received blood transfusions, albumin, recombinant human thrombopoietin, colony-stimulating factors, hetrombopag, or agents with similar targets within 14 days before the first dose.

  10. Women of childbearing potential must have a negative serum pregnancy test within 7 days before the first dose. Women of childbearing potential and men with female partners of childbearing potential must use effective contraception during treatment and for at least 9 months after the last dose.

Exclusion Criteria:

  1. Other malignancies within 2 years before the first dose, except cured localized cancers such as basal cell carcinoma, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, cervix or breast, and thyroid cancer.
  2. Previous treatment with any anti-HER2 therapy.
  3. Residual toxicities from previous treatment of Grade ≥2 according to NCI-CTCAE version 6.0, except alopecia.
  4. Active gastrointestinal bleeding.
  5. Central nervous system metastases and/or meningeal disease.
  6. Cerebrovascular accident, myocardial infarction, unstable angina, or uncontrolled arrhythmia (including QTc ≥470 ms, calculated using Fridericia's formula) within 6 months before the first dose.
  7. New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <55%.
  8. Active infection requiring systemic treatment, active tuberculosis, or asthma, except childhood asthma requiring no intervention during adulthood.
  9. History of noninfectious interstitial lung disease (ILD)/pneumonitis requiring steroid treatment, current ILD/pneumonitis, suspected ILD/pneumonitis on screening imaging, or other significant pulmonary conditions that may interfere with the assessment of drug-related pulmonary toxicity.
  10. Receipt of live vaccines within 28 days before the first dose, except seasonal influenza or inactivated COVID-19 vaccines.
  11. Major surgery within 28 days before the first dose.
  12. Radical radiotherapy within 28 days or palliative radiotherapy within 14 days before the first dose.
  13. Receipt of macromolecular targeted therapy, immunotherapy, or biologic therapy within 28 days; small-molecule cytotoxic chemotherapy within 14 days; or traditional Chinese medicine for anticancer treatment or minor surgery within 7 days before the first dose.
  14. Participation in another investigational drug study or use of an investigational device within 28 days before the first dose.
  15. History of severe allergic reactions to any monoclonal antibody or study drug excipients.
  16. Known history of psychotropic drug abuse or drug addiction.
  17. Known HIV infection or active syphilis.
  18. Breastfeeding, unless breastfeeding was discontinued before informed consent and will not resume during treatment. Breastfeeding may resume 9 months after the last study treatment.
  19. Any other medical condition, abnormal laboratory finding, or circumstance that, in the investigator's judgment, may interfere with study results or make participation inappropriate for the participant.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Cohort A: Colorectal Cancer

Participants with HER2-low advanced unresectable colorectal cancer will receive serplulimab 300 mg, HLX22 15 mg/kg, and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then trastuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

HLX22 is an investigational recombinant humanized anti-HER2 monoclonal antibody administered at a dose of 15 mg/kg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will last at least 90 minutes. If well tolerated, subsequent infusions may be shortened to at least 60 minutes. HLX22 is administered after serplulimab and before trastuzumab or pertuzumab.

Serplulimab is a humanized anti-PD-1 monoclonal antibody administered at a fixed dose of 300 mg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will be completed within 60 minutes (±10 minutes). If well tolerated, subsequent infusions may be shortened to 30 minutes (±10 minutes). Serplulimab is administered before HLX22.

Trastuzumab is an anti-HER2 monoclonal antibody administered by intravenous infusion on Day 1 of each 21-day cycle. The initial loading dose is 8 mg/kg, followed by a maintenance dose of 6 mg/kg every three weeks. The initial infusion will last at least 90 minutes. If well tolerated, subsequent infusions may be administered over at least 30 minutes. Trastuzumab is administered after HLX22 in Cohorts A, B, and C1.

Experimenteel: Cohort B: Gastric Cancer

Participants with HER2-low advanced unresectable gastric cancer, including gastroesophageal junction cancer, will receive serplulimab 300 mg, HLX22 15 mg/kg, and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then trastuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

HLX22 is an investigational recombinant humanized anti-HER2 monoclonal antibody administered at a dose of 15 mg/kg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will last at least 90 minutes. If well tolerated, subsequent infusions may be shortened to at least 60 minutes. HLX22 is administered after serplulimab and before trastuzumab or pertuzumab.

Serplulimab is a humanized anti-PD-1 monoclonal antibody administered at a fixed dose of 300 mg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will be completed within 60 minutes (±10 minutes). If well tolerated, subsequent infusions may be shortened to 30 minutes (±10 minutes). Serplulimab is administered before HLX22.

Trastuzumab is an anti-HER2 monoclonal antibody administered by intravenous infusion on Day 1 of each 21-day cycle. The initial loading dose is 8 mg/kg, followed by a maintenance dose of 6 mg/kg every three weeks. The initial infusion will last at least 90 minutes. If well tolerated, subsequent infusions may be administered over at least 30 minutes. Trastuzumab is administered after HLX22 in Cohorts A, B, and C1.

Experimenteel: Cohort C1: Biliary Tract Cancer

Participants with HER2-low advanced unresectable biliary tract cancer will receive serplulimab 300 mg, HLX22 15 mg/kg, and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then trastuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

HLX22 is an investigational recombinant humanized anti-HER2 monoclonal antibody administered at a dose of 15 mg/kg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will last at least 90 minutes. If well tolerated, subsequent infusions may be shortened to at least 60 minutes. HLX22 is administered after serplulimab and before trastuzumab or pertuzumab.

Serplulimab is a humanized anti-PD-1 monoclonal antibody administered at a fixed dose of 300 mg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will be completed within 60 minutes (±10 minutes). If well tolerated, subsequent infusions may be shortened to 30 minutes (±10 minutes). Serplulimab is administered before HLX22.

Trastuzumab is an anti-HER2 monoclonal antibody administered by intravenous infusion on Day 1 of each 21-day cycle. The initial loading dose is 8 mg/kg, followed by a maintenance dose of 6 mg/kg every three weeks. The initial infusion will last at least 90 minutes. If well tolerated, subsequent infusions may be administered over at least 30 minutes. Trastuzumab is administered after HLX22 in Cohorts A, B, and C1.

Experimenteel: Cohort C2: Biliary Tract Cancer

Participants with HER2-low advanced unresectable biliary tract cancer will receive serplulimab 300 mg, HLX22 15 mg/kg, and pertuzumab (840 mg loading dose followed by 420 mg), all administered intravenously on Day 1 of each 21-day cycle. The administration sequence is serplulimab, followed by HLX22 and then pertuzumab. Treatment will continue until loss of clinical benefit, unacceptable toxicity, withdrawal of informed consent, or other protocol-specified discontinuation criteria.

HLX22 is an investigational recombinant humanized anti-HER2 monoclonal antibody administered at a dose of 15 mg/kg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will last at least 90 minutes. If well tolerated, subsequent infusions may be shortened to at least 60 minutes. HLX22 is administered after serplulimab and before trastuzumab or pertuzumab.

Serplulimab is a humanized anti-PD-1 monoclonal antibody administered at a fixed dose of 300 mg by intravenous infusion on Day 1 of each 21-day cycle. The initial infusion will be completed within 60 minutes (±10 minutes). If well tolerated, subsequent infusions may be shortened to 30 minutes (±10 minutes). Serplulimab is administered before HLX22.

Pertuzumab is an anti-HER2 monoclonal antibody administered by intravenous infusion on Day 1 of each 21-day cycle. The initial loading dose is 840 mg, followed by a maintenance dose of 420 mg every three weeks. The initial infusion will last at least 60 minutes. If well tolerated, subsequent infusions may be administered over 30-60 minutes. Pertuzumab is administered after HLX22 in Cohort C2.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-Free Survival (PFS)
Tijdsspanne: From the first dose of study treatment to disease progression or death, assessed up to approximately 18 months.

Progression-free survival (PFS) is defined as the time from the first dose of study treatment to the first documented disease progression or death from any cause, whichever occurs first.

From the first dose of study treatment to disease progression or death, assessed up to approximately 18 months.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Objective Response Rate (ORR)
Tijdsspanne: From the first dose of study treatment through tumor response assessment, before subsequent anticancer treatment, assessed up to approximately 18 months.

Objective response rate (ORR) is defined as the percentage of participants whose best overall tumor response is complete response (CR) or partial response (PR), as assessed by the investigator using CT or MRI according to RECIST version 1.1.

From the first dose of study treatment through tumor response assessment, before subsequent anticancer treatment, assessed up to approximately 18 months.
Overall Survival (OS)
Tijdsspanne: From the first dose of study treatment to death from any cause, assessed up to approximately 36 months.

Overall survival (OS) is defined as the time from the first dose of study treatment to death from any cause.

From the first dose of study treatment to death from any cause, assessed up to approximately 36 months.
Disease Control Rate (DCR)
Tijdsspanne: From the first dose of study treatment through tumor response assessment, before subsequent anticancer treatment, assessed up to approximately 18 months.

Disease control rate (DCR) is defined as the percentage of participants whose best overall tumor response is complete response (CR), partial response (PR), or stable disease (SD), as assessed by the investigator using CT or MRI according to RECIST version 1.1.

From the first dose of study treatment through tumor response assessment, before subsequent anticancer treatment, assessed up to approximately 18 months.
Duration of Response (DOR)
Tijdsspanne: From the first documented CR or PR to disease progression or death, assessed up to approximately 18 months.

Duration of response (DOR) is defined as the time from the first documented complete response (CR) or partial response (PR), subsequently confirmed at least 4 weeks later, to the first documented disease progression or death from any cause, whichever occurs first.

From the first documented CR or PR to disease progression or death, assessed up to approximately 18 months.
Percentage of Participants With Adverse Events (AEs)
Tijdsspanne: From signing informed consent to 90 days after the last study treatment dose or initiation of new anticancer therapy, whichever occurs first; assessed up to approximately 36 months.

An adverse event (AE) is any unfavorable medical occurrence in a participant, whether or not it is considered related to study treatment. AEs will be identified through clinical evaluations, laboratory tests, and participant reports. Events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). The percentage of participants experiencing at least one AE will be summarized for each treatment cohort.

From signing informed consent to 90 days after the last study treatment dose or initiation of new anticancer therapy, whichever occurs first; assessed up to approximately 36 months.
Percentage of Participants With Serious Adverse Events (SAEs)
Tijdsspanne: From signing informed consent through 90 days after the last study treatment dose or initiation of new anticancer therapy, whichever occurs first; HLX22-related SAEs are monitored thereafter, up to approximately 36 months.

A serious adverse event (SAE) is an unfavorable medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes significant disability, or meets other medically important seriousness criteria. SAEs will be recorded regardless of their relationship to study treatment during the specified safety observation period. SAEs considered related to HLX22 will also be collected after this period. The percentage of participants experiencing at least one SAE will be summarized for each treatment cohort.

From signing informed consent through 90 days after the last study treatment dose or initiation of new anticancer therapy, whichever occurs first; HLX22-related SAEs are monitored thereafter, up to approximately 36 months.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 maart 2028

Studie voltooiing (Geschat)

1 december 2029

Studieregistratiedata

Eerst ingediend

10 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

10 november 2026

Eerst geplaatst (Werkelijk)

16 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren